GT Biopharma (GTBP) Competitors $2.31 -0.08 (-3.35%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends GTBP vs. NXTC, CARA, PULM, TRAW, TENX, COCP, XCUR, ATHA, GOVX, and MIRAShould you be buying GT Biopharma stock or one of its competitors? The main competitors of GT Biopharma include NextCure (NXTC), Cara Therapeutics (CARA), Pulmatrix (PULM), Traws Pharma (TRAW), Tenax Therapeutics (TENX), Cocrystal Pharma (COCP), Exicure (XCUR), Athira Pharma (ATHA), GeoVax Labs (GOVX), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. GT Biopharma vs. NextCure Cara Therapeutics Pulmatrix Traws Pharma Tenax Therapeutics Cocrystal Pharma Exicure Athira Pharma GeoVax Labs MIRA Pharmaceuticals NextCure (NASDAQ:NXTC) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, community ranking, dividends, media sentiment, institutional ownership, analyst recommendations and profitability. Does the media favor NXTC or GTBP? In the previous week, NextCure's average media sentiment score of -0.06 beat GT Biopharma's score of -0.50 indicating that NextCure is being referred to more favorably in the media. Company Overall Sentiment NextCure Neutral GT Biopharma Negative Do analysts rate NXTC or GTBP? NextCure currently has a consensus target price of $4.00, indicating a potential upside of 408.26%. GT Biopharma has a consensus target price of $11.00, indicating a potential upside of 368.09%. Given NextCure's higher probable upside, analysts clearly believe NextCure is more favorable than GT Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00GT Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has stronger earnings & valuation, NXTC or GTBP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNextCureN/AN/A-$62.72M-$2.09-0.38GT BiopharmaN/AN/A-$7.60MN/AN/A Does the MarketBeat Community believe in NXTC or GTBP? GT Biopharma received 37 more outperform votes than NextCure when rated by MarketBeat users. However, 64.52% of users gave NextCure an outperform vote while only 63.24% of users gave GT Biopharma an outperform vote. CompanyUnderperformOutperformNextCureOutperform Votes8064.52% Underperform Votes4435.48% GT BiopharmaOutperform Votes11763.24% Underperform Votes6836.76% Which has more risk & volatility, NXTC or GTBP? NextCure has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, GT Biopharma has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Do insiders & institutionals believe in NXTC or GTBP? 42.7% of NextCure shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 13.3% of NextCure shares are owned by insiders. Comparatively, 10.9% of GT Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is NXTC or GTBP more profitable? NextCure's return on equity of -62.50% beat GT Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets NextCureN/A -62.50% -53.67% GT Biopharma N/A -257.47%-131.09% SummaryNextCure beats GT Biopharma on 9 of the 13 factors compared between the two stocks. Get GT Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GTBP vs. The Competition Export to ExcelMetricGT BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.24M$6.56B$5.39B$9.14BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A9.7988.1017.53Price / SalesN/A331.481,285.4080.11Price / CashN/A22.6336.6032.90Price / Book0.435.064.954.67Net Income-$7.60M$154.90M$117.96M$224.69M7 Day Performance-6.75%2.59%2.49%3.32%1 Month Performance34.67%1.50%3.44%5.36%1 Year Performance-66.67%5.43%27.06%22.59% GT Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GTBPGT Biopharma2.9172 of 5 stars$2.31-3.3%$11.00+376.2%-66.1%$5.34MN/A0.008NXTCNextCure4.2775 of 5 stars$0.78-2.4%$4.00+412.8%-30.2%$21.85MN/A-0.3790CARACara Therapeutics4.0328 of 5 stars$4.77+0.4%$27.84+483.6%-31.4%$21.79M$8.69M-2.7380PULMPulmatrix0.9772 of 5 stars$5.95-1.0%N/A+245.2%$21.73M$10.01M-2.2520Positive NewsTRAWTraws Pharma0.4959 of 5 stars$7.13-11.5%N/AN/A$21.58M$226,000.00-0.0517Gap DownTENXTenax Therapeutics2.0236 of 5 stars$6.12-1.9%$16.00+161.4%-35.1%$20.86MN/A0.009COCPCocrystal Pharma2.5895 of 5 stars$2.05-7.2%$7.00+241.5%+22.2%$20.86MN/A-1.1110Positive NewsGap DownXCURExicure1.7233 of 5 stars$7.99-15.5%N/A+1,578.3%$20.82M$500,000.00-3.8650ATHAAthira Pharma3.609 of 5 stars$0.53-7.1%$13.83+2,534.9%-81.6%$20.30MN/A-0.1840Gap UpGOVXGeoVax Labs3.3121 of 5 stars$2.10-5.8%$14.20+576.2%-50.7%$19.82M$3.09M0.0010MIRAMIRA Pharmaceuticals2.7189 of 5 stars$1.17-7.1%$14.00+1,096.6%+45.7%$19.38MN/A-2.092 Related Companies and Tools Related Companies NextCure Alternatives Cara Therapeutics Alternatives Pulmatrix Alternatives Traws Pharma Alternatives Tenax Therapeutics Alternatives Cocrystal Pharma Alternatives Exicure Alternatives Athira Pharma Alternatives GeoVax Labs Alternatives MIRA Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GTBP) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
